BR112022003633A2 - Métodos para produção de arginase 1 recombinante humana e usos da mesma - Google Patents

Métodos para produção de arginase 1 recombinante humana e usos da mesma

Info

Publication number
BR112022003633A2
BR112022003633A2 BR112022003633A BR112022003633A BR112022003633A2 BR 112022003633 A2 BR112022003633 A2 BR 112022003633A2 BR 112022003633 A BR112022003633 A BR 112022003633A BR 112022003633 A BR112022003633 A BR 112022003633A BR 112022003633 A2 BR112022003633 A2 BR 112022003633A2
Authority
BR
Brazil
Prior art keywords
methods
recombinant human
producing recombinant
arginase
human arginase
Prior art date
Application number
BR112022003633A
Other languages
English (en)
Inventor
W Rowlinson Scott
Original Assignee
Aeglea Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeglea Biotherapeutics Inc filed Critical Aeglea Biotherapeutics Inc
Publication of BR112022003633A2 publication Critical patent/BR112022003633A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

métodos para produção de arginase 1 recombinante humana e usos da mesma. são descritos métodos para produzir arginase recombinante, tal como arginase 1 humana recombinante substituída por cobalto, peguilada. também são descritas composições farmacêuticas compreendendo tal arginase recombinante, bem como métodos de tratamento e usos de tal arginase recombinante
BR112022003633A 2019-08-30 2020-08-28 Métodos para produção de arginase 1 recombinante humana e usos da mesma BR112022003633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894319P 2019-08-30 2019-08-30
PCT/US2020/048536 WO2021041904A1 (en) 2019-08-30 2020-08-28 Methods for production of human recombinant arginase 1 and uses thereof

Publications (1)

Publication Number Publication Date
BR112022003633A2 true BR112022003633A2 (pt) 2022-06-07

Family

ID=72433097

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003633A BR112022003633A2 (pt) 2019-08-30 2020-08-28 Métodos para produção de arginase 1 recombinante humana e usos da mesma

Country Status (12)

Country Link
US (2) US20210189371A1 (pt)
EP (1) EP4022052A1 (pt)
JP (1) JP2022545738A (pt)
KR (1) KR20220082813A (pt)
CN (1) CN114729344A (pt)
AU (1) AU2020335905A1 (pt)
BR (1) BR112022003633A2 (pt)
CA (1) CA3149592A1 (pt)
IL (1) IL290817A (pt)
MX (1) MX2022002437A (pt)
TW (1) TW202122409A (pt)
WO (1) WO2021041904A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114350698B (zh) * 2021-11-30 2023-07-18 新泰市佳禾生物科技有限公司 人重组精氨酸酶i生产菌及其构建方法
WO2023201228A1 (en) * 2022-04-11 2023-10-19 Aeglea Biotherapeutics, Inc. Treatment of arginase 1 deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3778885T (lt) * 2008-10-31 2023-06-12 Aerase, Inc. Dirbtinai sukurtų žmogaus arginazių kompozicijos ir vėžio gydymo metodai
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
HRP20220406T1 (hr) * 2016-08-08 2022-05-27 Aerase, Inc. Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima
TW201910513A (zh) * 2017-08-16 2019-03-16 香港商鎧耀波麗堂（香港）有限公司 胺基酸耗竭治療的組合物及方法
KR20200122298A (ko) * 2017-12-05 2020-10-27 에어레이즈, 인크. 아르기나제 1 결핍을 치료하기 위한 방법 및 조성물
WO2021257523A1 (en) * 2020-06-15 2021-12-23 Aeglea Biotherapeutics, Inc. Use of arginase for treatment of influenza infections

Also Published As

Publication number Publication date
US20210189371A1 (en) 2021-06-24
US20240110172A1 (en) 2024-04-04
TW202122409A (zh) 2021-06-16
KR20220082813A (ko) 2022-06-17
JP2022545738A (ja) 2022-10-28
MX2022002437A (es) 2022-06-02
CN114729344A (zh) 2022-07-08
WO2021041904A1 (en) 2021-03-04
CA3149592A1 (en) 2021-03-04
EP4022052A1 (en) 2022-07-06
AU2020335905A1 (en) 2022-03-10
IL290817A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
ECSP14016014A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112018004078A2 (pt) composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
BR112018070189A2 (pt) método para seleção de proteínas recombinantes ricas em m6p
BR112022007710A2 (pt) Composições farmacêuticas de albumina e rapamicina
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112022003633A2 (pt) Métodos para produção de arginase 1 recombinante humana e usos da mesma
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
EA202192555A1 (ru) Комбинированная терапия для лечения рака